US Food and Drug Administration: Timothy Stenzel

The US Food and Drug Administration confirmed that Timothy Stenzel retired from his position at the agency as director of the Office of In Vitro Diagnostics in the Center for Devices and Radiological Health at the end of 2023. The agency is currently conducting a search for his successor. In the interim, Courtney Lias, director of the Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices, is serving in an acting capacity as director of the Office of In Vitro Diagnostics.

Stenzel joined FDA as director of the office in 2018. Prior to that he was COO at San Diego-based cancer testing firm Invivoscribe. Stenzel has also served as CSO at Quidel (now QuidelOrtho), CMO and VP of R&D at Asuragen (now part of Bio-Techne), and as an assistant professor of pathology and adjunct assistant professor of pathology at Duke University.